GULF PHARMACEUTICAL INDUSTRIES
🇪🇬Egypt
- Country
- 🇪🇬Egypt
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 1K
- Market Cap
- $295.3M
- Website
- http://www.julphar.net
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Huminsulin® Normal (soluble human insulin, reference)Drug: Julphar Insulin R (soluble human insulin, biosimilar)
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2015-12-24
- Lead Sponsor
- Julphar Gulf Pharmaceutical Industries
- Target Recruit Count
- 26
- Registration Number
- NCT02634515
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: Julphar Insulin N (human isophane insulin)Drug: Huminsulin® Basal (NPH, human isophane insulin)
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2020-07-02
- Lead Sponsor
- Julphar Gulf Pharmaceutical Industries
- Target Recruit Count
- 85
- Registration Number
- NCT02634528
- Locations
- 🇩🇪
Profil Neuss GmbH, Neuss, Germany
Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III
Phase 1
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: human biphasic insulinDrug: human biphasic insulin, reference
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2016-08-02
- Lead Sponsor
- Julphar Gulf Pharmaceutical Industries
- Target Recruit Count
- 73
- Registration Number
- NCT02631928
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
© Copyright 2025. All Rights Reserved by MedPath